Schvartsman G, et al. – This retrospective study explored if single–agent chemotherapy (3rd–line or beyond) would yield improved overall response rate (ORR) when given after exposure to programmed death–(ligand)1 inhibitors (anti–PD1) in metastatic non–small cell lung cancer (NSCLC). The confirmed ORR to single–agent chemotherapy after immunotherapy exposure was higher as compared to historical data from the pre–anti–PD1 era, and approached ORR to first–line platinum–based chemotherapy in NSCLC patients.